Comparing prognostic value of preoperative platelet indexes in patients with resectable gastric cancer

Shi, Hongtai; Wang, Hongsheng; Pan, Jie; Liu, Zhenhua; Li, Zuoan

doi:10.1038/s41598-022-10511-6

Cited by 12 publications

(13 citation statements)

References 29 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MPV/PC was significantly lower in patients with esophageal squamous cell carcinoma than in the control group, and a lower MPV/PC was associated with local progression and a worse prognosis [ 23 ]. Similarly, a lower MPV/PC was associated with poor prognosis in patients with gastric cancer, and MPV/PC has a higher accuracy than NLR or PLR in predicting the prognosis of gastric cancer [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Mean platelet volume/platelet count ratio in combination with tumor markers in colorectal cancer: a retrospective clinical study

2023

View full text Add to dashboard Cite

Background Mean platelet volume (MPV) is a marker of platelet activation, which is usually negatively correlated with platelet count (PC). The ratio of MPV to PC (MPV/PC) has an essential role in the diagnosis of multiple malignancies. However, only a few studies investigated the value of MPV/PC in colorectal cancer (CRC) and the combination of MPV/PC with tumor markers in CRC. This retrospective clinical study aimed to evaluate the diagnostic value of MPV/PC and tumor markers (CA72-4, CA125, CA199) used alone or in combination in CRC. Methods 200 patients with CRC and 317 patients with colorectal benign polypus pathologically diagnosed during 2019/01/04 to 2022/06/30 were included. Hematological and pathological parameters of the above patients were collected, data were analyzed with Student’s t-test, one-way ANOVA or Kruskal-Wallis H test and receiver operating characteristic (ROC) curve, and ROC curve was used to evaluate the diagnostic value of tumor markers and MPV/PC used alone or in combination in CRC. Results The MPV/PC in CRC group was significantly lower than the control group (P < 0.0001). Among the three tumor markers, higher CA125 was correlated with distant metastasis and lower differentiation (P < 0.05), increased CA72-4 indicated positive nerve invasion (P = 0.0174), and elevated CA199 was associated with lymphatic metastasis and positive vascular invasion (P < 0.05). For subgroups regarding tumor anatomical location, both CA125 and CA199 were higher in colon cancer group than rectum cancer group (P = 0.0322, P = 0.0094). MPV/PC was associated with tumor infiltration, regional lymph node metastasis, differentiation and nerve invasion (P < 0.05) and the combination of MPV/PC with the three tumor markers produced a larger AUC with higher sensitivity, specificity and Yuden index than MPV/PC or the three tumor markers used alone to distinguish between CRC and colorectal polyps. Conclusion Preoperative MPV/PC in peripheral blood of patients with CRC was lower than the control group. Meanwhile, the combined detection of tumor markers with MPV/PC can improve the diagnostic value of CRC, revealing the potential of MPV/PC as a promising screening tool in CRC early diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Mean platelet volume/platelet count ratio in combination with tumor markers in colorectal cancer: a retrospective clinical study

2023

View full text Add to dashboard Cite

show abstract

“…The decrease of MPV when treatment applied was also reported in the patients with pancreatic cancer ( 60 , 70 ), squamous cell carcinoma of the esophagus ( 71 ), and gastric cancer ( 72 ). Compared with other clinical covariates (e.g., neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, combined neutrophil-platelet score and systemic immune-inflammation index), the ratio of MPV/platelet count was more accurate in determining the prognosis of gastric cancer patients and could be an independent prognostic factor for patients with resectable gastric cancer ( 73 ). Further, some studies investigated the cause of increased MPV in cancer patients.…”

Section: Clinical Applications Of Platelets For Cancer Patientsmentioning

confidence: 99%

Platelet detection as a new liquid biopsy tool for human cancers

Chen

Hou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Cancer is still a leading cause of death worldwide and liquid biopsy is a powerful tool that can be applied to different stages of cancer screening and treatment. However, as the second most abundant cell type in the bloodstream, platelets are isolated through well-established and fast methods in clinic but their value as a BioSource of cancer biomarkers is relatively recent. Many studies demonstrated the bidirectional interaction between cancer cells and platelets. Platelets transfer various proteins (e.g., growth factors, cytokine, chemokines) and RNAs (e.g., mRNA, lncRNA, miRNA, circRNA) into the tumor cells and microenvironment, leading the stimulation of tumor growth and metastasis. In turn, the platelet clinical characteristics (e.g., count and volume) and contents (e.g., RNA and protein) are altered by the interactions with cancer cells and this enables the early cancer detection using these features of platelets. In addition, platelet-derived microparticles also demonstrate the prediction power of being cancer biomarkers. In this review, we focus on the clinical applications of platelet detection using the platelet count, mean platelet volume, platelet RNA and protein profiles for human cancers and discuss the gap in bringing these implementations into the clinic.

show abstract

“… 13 , 14 Therefore, the NLR is a prognostic indicator in patients with NSCLC, 5 , 15 , 16 small cell lung cancer, 17 , 18 and other cancers. 19 , 20 , 21 , 22 Specifically, Nathan et al revealed that the NLR is a significant prognostic indicator of survival in patients treated for early‐stage NSCLC with stereotactic radiation. 5 Moreover, patients with stage IV NSCLC 15 with a high NLR were also significantly associated with poor OS, as were those treated with nivolumab.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, a high NLR has been demonstrated to be associated with low overall survival (OS) in patients with solid tumors 13,14 . Therefore, the NLR is a prognostic indicator in patients with NSCLC, 5,15,16 small cell lung cancer, 17,18 and other cancers 19–22 . Specifically, Nathan et al revealed that the NLR is a significant prognostic indicator of survival in patients treated for early‐stage NSCLC with stereotactic radiation 5 .…”

Section: Introductionmentioning

confidence: 99%

Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer

Fan

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

Background This study focused on the relationship between the neutrophil‐to‐lymphocyte ratio (NLR) and the dose of organs at risk in patients with stage II–III non‐small cell lung cancer (NSCLC) receiving intensity‐modulated radiotherapy. Methods The clinical characteristics and dosimetric parameters of 372 patients were collected retrospectively. A high NLR was defined as that ≥1.525. Survival analysis was conducted using the Kaplan–Meier and Cox regression analysis. Least absolute shrinkage and selection operator (LASSO) analysis was conducted to select appropriate dosimetric parameters. The risk factors of NLR were evaluated using univariate and multivariate logistic regression analyses. Results Patients with a high NLR had poorer progression‐free survival (PFS) ( p = 0.011) and overall survival (OS) ( p = 0.061). A low NLR (<1.525) predicted better PFS (hazard ratio [HR] 0.676, 95% confidence interval [CI]: 0.508–0.900, p = 0.007) and OS (HR 0.664, 95% CI: 0.490–0.901, p = 0.009). The aorta dose differed between the low and high NLR groups (all <0.1) in the univariate analysis. An aorta V10 was confirmed as a significant risk factor for a high NLR (odds ratio [OR] 1.029, 95% CI: 1.011–1.048, p = 0.002). Receiving chemotherapy before (OR 0.428, 95% CI: 0.225–0.813, p = 0.010) and during (OR 0.491, 95% CI: 0.296–0.815, p = 0.006) radiotherapy were predictive factors of a low NLR. Conclusion The aorta dose was significantly associated with a high NLR. Patients with stage II–III NSCLC with a high NLR had poorer prognosis. Receiving chemotherapy before and/or during radiotherapy predicted a low NLR.

show abstract

Comparing prognostic value of preoperative platelet indexes in patients with resectable gastric cancer

Cited by 12 publications

References 29 publications

Mean platelet volume/platelet count ratio in combination with tumor markers in colorectal cancer: a retrospective clinical study

Mean platelet volume/platelet count ratio in combination with tumor markers in colorectal cancer: a retrospective clinical study

Platelet detection as a new liquid biopsy tool for human cancers

Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer

Contact Info

Product

Resources

About